Compare VanEck Video Gaming and eSports ETF (ESPO) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Video Gaming and eSports ETF vs GSK plc — how do they compare? VanEck Video Gaming and eSports ETF trades at $99.92 (market cap $248.06M), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 370.4× VanEck Video Gaming and eSports ETF's market cap, and GSK plc pays a 3.9% dividend while VanEck Video Gaming and eSports ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 66 Days and GSK plc for 93 Days on average.
| ESPO | GSK | |
|---|---|---|
Market Cap | $248.06M | $91.88B |
Volume | 13,622 | 7,730,529 |
Sector | Sector/Thematic | Health |
52-Week High | $118.68 | $61.18 |
52-Week Low | $85.25 | $43.24 |
Typical Hold Time | 66 Days | 93 Days |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $97.32, down 0.33% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $97 and resistance at $98. Financial ratios are unavailable in the provided data, limiting fundamental insight. No recent news is available to drive sentiment.
The outlook is mixed: technicals suggest upward momentum, but the absence of fundamental data and recent news creates uncertainty. Risks include market volatility and lack of visibility on financial health. Investors need updated earnings and guidance for a clearer investment case.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
